Program
apitegromab
Also written as “Apitegromab” and “SRK-015”.
Its studies are mostly in Spinal Muscular Atrophies of Childhood · Muscular Dystrophy, Facioscapulohumeral · Obesity, led by Scholar Rock.
Furthest: phase 3, since Dec 1, 20216 company-led studies, 3 open or runningNext primary completion: Jun 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Scholar Rock | 63 open or running | phase 3since Dec 1, 2021 | Apr 16, 2019 | Jun 2028phase 2 · NCT07435129 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 16, 2019First study: phase 2 study in Muscular Atrophy, SpinalFirst studyNCT03921528 · 58 enrolled · United States, Italy, Netherlands and more
- Dec 1, 2021Phase 3 study in Muscular Atrophy, SpinalNCT05156320 · 188 enrolled · United States, Belgium, France and more
- Nov 7, 2022Phase 3 study in Muscular Atrophy, SpinalNCT05626855 · 238 enrolled · United States, Belgium, France and more
- May 22, 2024Phase 2 study in OverweightNCT06445075 · 102 enrolled · United States
- Apr 16, 2025Phase 2 study in Muscular Atrophy, SpinalNCT07047144 · 52 planned · United States, Belgium, France and more
- Feb 10, 2026Phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT07435129 · 60 planned · United States
Ahead
- Nov 1, 2026Primary completion: phase 3 study in Muscular Atrophy, SpinalNCT05626855
- Jun 2028Primary completion: phase 2 study in Muscular Dystrophy, FacioscapulohumeralNCT07435129
- Nov 2028Primary completion: phase 2 study in Muscular Atrophy, SpinalNCT07047144
TargetBeta
MSTN →read by rule
“Growth/differentiation factor 8 inhibitor”ChEMBL 37, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07435129Muscular Dystrophy, Facioscapulohumeral · United States | 2 | Recruiting | Jun 2028 | 60 |
| NCT07047144Muscular Atrophy, Spinal · United States, Belgium, France and more | 2 | Recruiting | Nov 2028 | 52 |
| NCT06445075Overweight · United States | 2 | Completed | Mar 4, 2025 | 102 |
| NCT05626855Muscular Atrophy, Spinal · United States, Belgium, France and more | 3 | Active, not recruiting | Nov 1, 2026 | 238 |
| NCT05156320Muscular Atrophy, Spinal · United States, Belgium, France and more | 3 | Completed | Dec 18, 2024 | 188 |
| NCT03921528Muscular Atrophy, Spinal · United States, Italy, Netherlands and more | 2 | Completed | Jan 19, 2021 | 58 |
How it is read
Names in the registry
- “Apitegromab”, 5 entries
- “SRK-015”, 1 entry
Conditions, from the studies’ own filings
- Spinal Muscular Atrophies of Childhood, 4 studies
- Muscular Dystrophy, Facioscapulohumeral, 1 study
- Obesity, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.